Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2065]

New MM patients with high levels of circulating tumour cells distinguished by...

Dr Cathelijne Fokkema - Erasmus MC Cancer Institute, Rotterdam, Netherlands

New MM patients with high levels of circulating tumour cells distinguished by increased bone marrow plasma cell proliferation ( Dr Cathelijne Fokkema - Erasmus MC Cancer Institute, Rotterdam, Netherlands )

Exceptional response to oral metronomic chemotherapy in a rare case of...

Dr Akhil Kapoor - Tata Memorial Hospital, Mumbai, India

Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal mucosal melanoma ( Dr Akhil Kapoor - Tata Memorial Hospital, Mumbai, India )

PARP inhibitors in prostate cancer: Case based testing and clinical decisions

Dr Neal Shore and Prof Fred Saad

PARP inhibitors in prostate cancer: Case based testing and clinical decisions ( Dr Neal Shore and Prof Fred Saad )

OncoAlert and ecancer - ESMO 2021 Day 2

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Long-term outcomes and complications in cancer patients who have recovered from...

Dr David Pinato - Imperial College London, London, UK

Long-term outcomes and complications in cancer patients who have recovered from COVID-19 ( Dr David Pinato - Imperial College London, London, UK )

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or...

Prof Thomas Powles - Queen Mary University of London, London, UK

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa ( Prof Thomas Powles - Queen Mary University of London, London, UK )

ESMO President: What to watch for at ESMO 2021

Prof Solange Peters - ESMO President

ESMO President: What to watch for at ESMO 2021 ( Prof Solange Peters - ESMO President )

OncoAlert and ecancer - ESMO 2021 preview

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 preview ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and...

Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM ( Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain )

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or...

Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients ( Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA )

Should every transplant eligible NDMM patient receive a transplant?

Prof Morie Gertz - Mayo Clinic, Rochester, USA

Should every transplant eligible NDMM patient receive a transplant? ( Prof Morie Gertz - Mayo Clinic, Rochester, USA )

Vaccinations in myeloma patients including for COVID-19

Prof Heinz Ludwig - Wilhelminen Cancer Research Institute, Vienna, Austria

Vaccinations in myeloma patients including for COVID-19 ( Prof Heinz Ludwig - Wilhelminen Cancer Research Institute, Vienna, Austria )

More from ecancer